OBIO
Orchestra BioMed Holdings, Inc.
$3.65
-0.04 (-1.08%)
At close · Jul 15
Market Cap
$222.76M
Shares
59,880,715
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$33.48M
+1169.2%
FY2025
Net Income
-$52.7M
+13.6%
FY2025
Gross Margin
99.43%
+7.2pp
FY2025
Operating Margin
-154.73%
+2282.8pp
FY2025
Diluted EPS
-$1.11
+33.1%
FY2025
Operating Cash Flow
-$48.96M
+3.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $32.72M | $33.48M | $2.64M | $2.76M | $3.53M | — | — | |
| $3.94M | — | — | $3.85M | $50K | — | — | |
| $178K | $190K | $204K | $186K | $211K | — | — | |
| $32.55M | $33.29M | $2.43M | $2.57M | $3.32M | — | — | |
| — | 99.43% | 92.27% | 93.26% | 94.03% | — | — | |
| $60.48M | $58.19M | $42.8M | $33.82M | $21.95M | — | — | |
| — | — | — | — | $2.96M | $274.76K | $129.99K | |
| $27.02M | $26.91M | $23.93M | $20.26M | $14.03M | — | — | |
| — | $327K | $308K | $287K | $222K | — | — | |
| — | — | — | — | — | — | $179.99K | |
| $87.69M | $85.29M | $66.94M | $54.27M | $36.19M | — | — | |
| -$54.96M | -$51.81M | -$64.3M | -$51.51M | -$32.66M | -$394.76K | — | |
| — | -154.73% | -2437.49% | -1866.16% | -924.34% | — | — | |
| — | -$51.48M | -$63.99M | -$51.22M | -$32.44M | — | — | |
| — | — | — | — | $345.14K | $16K | — | |
| — | — | -$11K | — | — | — | — | |
| — | — | -$68K | -$18K | $1.03M | — | — | |
| — | $0 | — | — | — | — | — | |
| -$54.64M | -$52.7M | -$61.02M | -$49.12M | -$33.61M | -$378.75K | -$173.54K | |
| — | -157.4% | -2313.27% | -1779.71% | -951.26% | — | — | |
| — | -$52.96M | -$61.02M | — | — | — | $1.5M | |
| -$54.71M | -$52.69M | -$60.96M | -$49.12M | -$33.62M | — | — | |
| USD/shares | — | -$1.11 | -$1.66 | -$1.48 | -$2.24 | -$0.02 | — |
| USD/shares | — | -$1.11 | -$1.66 | -$1.48 | -$2.24 | -$0.02 | — |
| shares | — | 47.75M | 36.82M | 33.23M | 14.99M | 20.45M | 16M |
| shares | — | 47.75M | 36.82M | 33.23M | 14.99M | 20.45M | 16M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.53×
EV/EBIT
—
Biotechnology median 26.49×
P/E (TTM)
—
Biotechnology median 7.39×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Partnership Revenue | $32,871,000 | $2,005,000 | $2,106,000 | $2,862,000 |
| Product | $611,000 | $633,000 | $654,000 | $671,000 |